when to sell zom stock

Should you buy or sell zomedica (Zom) stock?

Jan 08, 2022 · Yet despite that, the stock has been trading at around 36.8 times forward earnings. Instead of thinking about selling Zoom stock, it's probably …

Is Zom a buy or sell in 2020?

Feb 04, 2022 · Zom stock has traded in a 52-week range with $2.91 as the ceiling and $0.24 as the floor. It is presently trading at $0.31 as of writing, closer to its 52-week bottom. The current price is testing the support formed by the Q4 2019 price at 0.3048, which has so far held firm.

Is Zoom stock still a good buy?

Mar 22, 2021 · However, ZOM has lost nearly 16% since its first sale of the platform on March 16, and the stock continues to suffer. Selling Shares to Stay Afloat On February 16, ZOM announced that the underwriter of its previously announced public offering had exercised in full it’s over-allotment option to purchase additional common shares of the company at a price of $1.90 per …

Is Zom a leader in the medical – pharmaceuticals industry?

Technical Analysis for ZOM - Zomedica Pharmaceuticals Corp. Buy or Sell? ZOM closed up 1.8 percent on Thursday, April 14, 2022, on 44 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Should I keep Zomedica stock?

Therefore, it's safe to say that ZOM stock is a highly speculative investment, and investors should only take small positions in this stock. Still, it's perfectly fine to hold a few shares of ZOM stock in the hope that the company will turn itself around in 2022.Jan 7, 2022

Is ZOM stock expected to go up?

The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +292.16% increase from the last price of 0.31.

Is Zomedica overvalued?

Is Zomedica stock overvalued? Zomedica shares soared near the beginning of 2021, but then plummeted over 80% from their highest share price. In retrospect, it seems like shareholders had pie-in-the-sky dreams for Truforma, the company's point-of-care diagnostic system.

Why is ZOM stock dropping?

The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.Nov 18, 2021

What is ZOM target price?

Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.29

Is Zomedica undervalued?

InvestorPlace's Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.Jun 28, 2021

Will Zomedica recover?

ZOM stock will likely struggle to recover in price over the next few months. It's going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.Oct 7, 2021

Is Sundial growers a buy?

The price has been going up and down for this period, and there has been a -18.65% loss for the last 2 weeks....Predicted Opening Price for Sundial Growers Inc. of Thursday, April 21, 2022.Fair opening price April 21, 2022Current price$0.53$0.53 (Undervalued)

Is Acasti Pharma a good stock to buy?

Is ACASTI PHARMA Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: ACST) stock is to Buy ACST stock.

Is Zomedica a pump and dump?

Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.Jan 21, 2021

NASDAQ: ZM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The videoconferencing company's share price has fallen a long way from the peak it hit earlier in the pandemic

Shares of Zoom Video Communications ( ZM 5.72% ) have been on the skids since peaking in late 2020. Investors who have held on this long have seen the stock fall by more than two-thirds, and many may be eager to exit their positions.

Why Zoom's down

In early 2020, the market went nuts for Zoom because its revenues were rocketing higher. However, many of the businesses that were scrambling for work-from-home solutions back then likely see their Zoom subscriptions as a little less important now.

NASDAQ: ZM

The rapidly increasing demand that inspired the market to push Zoom's stock price through the roof has tapered off. Yet it's important for investors to note that Zoom continues to grow at an impressive pace.

Why Zoom could rise again

It's been more than a year since Microsoft ( MSFT 5.11% ) dropped its 40-minute time limit on video chats for non-paying users of its Teams service. Teams' popularity has grown, but demand for videoconferencing appears high enough that Microsoft's offering probably isn't a major threat to Zoom.

Not time to sell

The consumer market for hosting virtual events is growing fast, and I believe we've only seen the tip of the iceberg. Competition for the enterprise market will make Zoom's growth in 2022 seem relatively underwhelming, but now isn't the time to let go of this stock.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.

Zom Stock News

The earnings report of 25 February 2022 will constitute a ZOM stock news of interest. The only significant news of note after the retirement of erstwhile CEO Robert Cohen back in October 2021 was the recent press conference by the new CEO, which provided an update on the progress of new diagnostic assay developments.

Will Zom Stock Go Up?

Zomedica’s share price has been in a slump for the major part of 2021.

Zom Stock Forecast 2022

What is the Zom stock forecast for 2022? The Zom stock forecast 2022 is a medium-term forecast that aims to predict the Zom stock price in the next few months. Following the completion of the double top on the weekly chart, price action is now trading around the measured move’s completion zone.

Zom Stock Forecast 2025

The Zom stock forecast 2025 retains the bearish outlook that has permeated the stock for the latter part of 2021. There aren’t positive fundamentals to suggest a change in sentiment. Any rallies would be purely speculative and would only provide opportunities for traders looking to make huge gains by shorting the stock.

ZOM: Monthly Chart

The monthly chart shows that the RSI still has room to head into the oversold region, while there is a lack of good buying volume. Indeed, trading volumes are fragile. The current support at 0.3048 remains the only factor holding price activity from declining further.

Zom Stock forecast 2030

If you have a long term view and want to get some insight via the Zom stock forecast 2025, then this is where it gets interesting. CEO Larry Heaton recently delivered an address where he outlined the company’s strategy for driving sales of Truforma. This is to be based on three pillars:

Is Zom a Good Stock to Buy

ZOM stock could provide some good gains in the long term if its veterinary diagnostic and therapeutic technologies can gain sufficient market traction. However, the stock remains a speculative investment that owed its previous tops to the Reddit meme that lifted other stocks like GameStop and AMC.

Why is ZOM stock dropping?

Zomedica shares have fallen more than 30 percent in the past month and 80 percent from their Feb. 2021 peak. Zomedica stock’s decline can be linked to some investors getting frustrated with delays in ramping up Truforma platform sales.

Will Zomedica (ZOM) stock go back up?

In its latest corporate update, Zomedica implied that setting up the internal sales force for Truforma is progressing well and sales should begin to materialize soon. It said it expects to close the year with 15 sales representatives, and other industry professionals will support the team.

Zomedica's (ZOM) stock price forecast

Wall Street analysts' average price target of $1.20 for ZOM suggests the stock could rise more than 90 percent in the next 12 months.

Zomedica's FDA approval

Zomedica’s Truforma platform, which produces diagnostic results on the spot, went on sale in Mar. 2021. Its sales are still minimal (just over $14,000 in the first quarter) as the company works on the internal marketing team.

Should you buy or sell Zomedica (ZOM) stock?

Penny stocks require extra caution, and Zomedica stock is no exception. But ZOM looks like it could pay off well for patient investors—at about 80 percent below its peak, it could be a good deal.

NASDAQ: ZM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Zoom is putting up impressive numbers amid pandemic-induced volatility

Looking back at the last two years, there may be no stock more representative of the pandemic's impact on the stock market than Zoom Video Communications ( ZM -1.30% ). After growing parabolically in 2020, the stock has come crashing back to earth and is down 45% year to date at the time of this writing.

Two-year comparisons are impressive

For better or worse, Zoom has become synonymous with the pandemic. Its rise to prominence and the resulting performance were tied to a massive need for video communications at the height of lockdowns. This demand pulled forward a ton of growth and warped some investors' views of the company's fundamentals.

NASDAQ: ZM

Because of this, it is helpful to take a look at Zoom's performance as compared to 2019. After all, year-over-year comparisons in 2021 are facing some awfully tough comparisons to 2020, when demand was at its peak. The chart below compares Zoom's Q3 of 2022 (ending Oct. 31, 2021) to the corresponding quarter two years ago.

More than just video chat

All successful companies find ways to keep expanding their business in order to create new revenue streams and remain relevant in an ever-changing world. In order to do this, businesses need the cash to invest in research and development and capital improvements.

Buy, sell, or hold?

For a company like Zoom that has been so tied in investors' minds to the pandemic, it can be difficult to take a step back and see the forest for the trees. Taken without the noise of the past two years, Zoom is clearly a buy for existing shareholders or those investors looking to start a position.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.

How much money did Zom make from stock sale?

ZOM has generated roughly $200 million in proceeds from the stock sale and intends to use it for the continued development of its diagnostic platforms, strategic acquisitions and for other general corporate and working capital purposes.

How much did Zom make in 2020?

ZOM also generated roughly $30 million last July 2020 through a public offering of its common shares.

What is a BAW in ZOM?

Investors were looking forward to ZOM’s first sale of its Truforma diagnostic product, which uses Bulk Acoustic Wave (BAW) technology developed by Qorvo, Inc. ( QRVO ). The product delivers a non-optical and fluorescence-free detection system for use at the point-of-care. However, ZOM has lost nearly 16% since its first sale of the platform on March 16, and the stock continues to suffer.

Is Zom a pharmaceutical company?

ZOM operates in a small niche in the pharmaceutical space, focused solely on developing products for companion animals. So, a lot is riding on the company’s commercialization of its Truforma diagnostic product. However, ZOM has so far failed to impress investors and the stock plunged sharply after its first sale.

Earnings Recap

Zomedica recorded a third-quarter 2021 net loss of $6.3 million, or $0.01 per share, up from a loss of $5 million, or $0.01 per share reported in the same quarter last year. Notably, lower research and development (R&D) costs were offset by a rise in selling, general and administrative (SG&A) expenses.

Risk Analysis

According to the new TipRanks’ Risk Factors tool, Zomedica stock is at risk mainly from three factors: Finance and Corporate, Production, and Ability to Sell, which contribute 48%, 15%, and 11%, respectively, to the total 62 risks identified for the stock.

Latest Stocks Videos

In The Money: Groundhog Day: Mega-Cap Tech Stocks Out From the Shadows? Feb 02, 2022

TipRanks

TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.

Two-Year Comparisons Are Impressive

• For better or worse, Zoom has become synonymous with the pandemic. Its rise to prominence and the resulting performance were tied to a massive need for video communications at the height of lockdowns. This demand pulled forward a ton of growth and warped some investors' views of the company's fundamentals. Because of this, it is helpful to take a l...

See more on fool.com

More Than Just Video Chat

Buy, Sell, Or Hold?